MRSA

Pau d'Arco has shown promising results against MRSA. A separate Korean study found MRSA in 40.9% of all culture-confirmed spinal infections. One multicentre Korean study reported that MRSA accounted for 75% of Staphylococcus aureus spinal implant infections. First- and second-generation cephalosporins do not provide coverage against methicillin-resistant Staphylococcus aureus. MRSA is a bacterium notorious for antibiotic resistance. Pau d'Arco functions as a natural antibiotic with documented effects on bacterial infections, including those resistant to conventional treatment. MRSA is an important pathogen in postoperative spinal infections in Korea. The high MRSA prevalence in Korea supports concern that narrow cephalosporin-only prophylaxis may be inadequate in high-risk settings.